------------------------------------------------------------
[link removed]


**
Advocates Take the Bullhorn: New resources on AVAC.org
------------------------------------------------------------
May 29, 2020

Dear Advocate,

In case you missed it, AVAC has a number of new resources to support our collective advocacy for HIV prevention research and an equitable, evidence-based response to COVID-19.

HIV Advocates Demand an Ethical Response to COVID-19
* To accelerate search for COVID-19 vaccine, look to HIV and act globally ([link removed]) , this commentary in Devex ([link removed]) by AVAC’s Mitchell Warren calls for vaccine development and a response to COVID-19 driven by public health, engaged communities and global collaboration, not nationalism.
* In a live chat with aidsmap ([link removed]) , AVAC Fellow ([link removed]) Winifred Ikilai ([link removed]) makes the case for Good Participatory Practice in COVID-19 vaccine development and delivery.
* HIV Advocates Respond to the COVID-19 Crisis ([link removed]) - On USAID’s blog, the CASPR Coalition ([link removed]) writes about the role HIV advocates must play so that resources and networks empower communities responding to COVID-19.
* COVID-19, Yes but HIV Needs Attention Too ([link removed]) - In this article in Malawi’s Times ([link removed]) newspaper, 2019 AVAC Fellow Josephine Chinele ([link removed]) , from the Pakachere Institute for Health and Development Communication, exhorts leaders to safeguard gains in HIV while tackling COVID-19.
* Ethical Conduct of SARS-CoV-2 Vaccine Challenge Studies ([link removed]) - AVAC and TAG respond to the call for human challenge studies in vaccine research–The WHO Working Group has articulated important criteria for assessing a challenge study, but we believe that they left out the most important one: Until there is an approved treatment, a challenge trial with a potentially fatal and as-yet untreatable pathogen is unacceptable.
* How COVID-19 Must Transform US Global Health Strategy ([link removed]) - Writing in The Hill, AVAC Executive Director Mitchell Warren and President of Friends of the Global Fight Against AIDS, Tuberculosis and Malaria ([link removed]) Chris Collins challenge us not just to survive this crisis but to seize this moment and begin work on a more sustainable future–one in which the next global pandemics land in a more prepared, more secure and healthier world.
* A look at the pipeline ([link removed]) : COVID-19 diagnostics, therapeutics and a potential vaccine. This document also links to a number of additional resources tracking these developments.



Unprecedented focus on vaccine development for COVID-19 put a new perspective on HIV Vaccine Awareness Day (HVAD) on May 18.
There’s never been more at stake or more opportunity to build global capacity to ethically develop and deliver vaccines, which are essential to eventually end HIV and face future epidemics.

* HIV Vaccines: Are You Aware? ([link removed]) - This op-ed placed in Zambia’s Daily Mail Limited ([link removed]) 2020 AVAC Fellow Esnart Sikazindu ([link removed]) spells out why continued investment in HIV vaccine research is essential.
* AVAC’s new report, Five “P”s to ([link removed]) Watch ([link removed]) : Platforms, process, partnerships, payers and participatory practices that drive vaccine development ([link removed]) , connects key issues and lays out how HIV vaccine research is making the search for a COVID-19 vaccine faster, smarter and more inclusive.
* AVAC’s latest podcast episode of Px Pulse ([link removed]) features leading voices from HIV vaccine and prevention research talking about the intersection of HIV and COVID-19.
* Check out key messages ([link removed]) on priorities and unique opportunities for vaccine advocacy for HIV, COVID-19 and future epidemics.


Best,
AVAC


P.S.

AVAC is accepting applications ([link removed]) for the Good Participatory Practice Online
Training course to run June 15^th-August 21^st. This course offering will draw from various disease areas, including COVID-19 and the need for quick and responsive GPP in this research environment.


============================================================
Forward This Issue Do you know someone who might be interested in receiving this newsletter?
** Forward > ([link removed])

Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
** Unsubscribe > ([link removed])

Contact Us T: +1 212 796 6423
E: ** [email protected] (mailto:[email protected])
W: ** www.avac.org ([link removed])
** ([link removed])
** ([link removed])
** ([link removed])